• Ionizing Radiation and Altered Neuronal Differentiation

  2026-09-01

  The reference study shows that ionizing radiation can redirect neuronal differentiation in C17.2 mouse neural stem-like cells rather than simply depleting neural precursor populations. Its experiments connect increased neurite outgrowth and altered neurotransmitter-related gene expression to PI3K-STAT3-mGluR1 and PI3K-p53 signaling, providing a mechanistic framework for studying radiation-associated neural dysfunction.

• SAG Protects Frataxin-Deficient Astrocytes

  2026-09-01

  Vicente-Acosta et al. showed that frataxin depletion drives mitochondrial stress, reactive astrocyte features, and neuron-damaging secretory activity in cultured human astrocytes. Chronic Smoothened receptor agonist treatment with SAG prevented many of these abnormalities, supporting Hedgehog pathway activation as a strategy for studying astrocyte-mediated neurodegeneration in Friedreich’s ataxia.

• IGFBP2–THBS1 Axis in GH Therapy for Short Stature

  2026-08-31

  The reference study identifies an IGFBP2–THBS1 regulatory axis that connects growth hormone treatment with IGF-1 signaling, chondrocyte proliferation, and hypertrophic differentiation in idiopathic short stature. Its combination of patient plasma data, bioinformatic prediction, and gain- and loss-of-function experiments provides a mechanistic framework for understanding variable responses to growth hormone therapy.

• Griseofulvin Microtubule Assay Workflow

  2026-08-31

  Build a practical Griseofulvin workflow that connects fungal growth inhibition with microtubule mechanism profiling. The approach combines formulation control, time-resolved phenotyping, and a reference-informed flow-cytometry strategy to distinguish microtubule effects from general cellular stress.

• TP53, ATM, and MDM2 Shape Calicheamicin Response

  2026-08-30

  This study uses genome-wide CRISPR/Cas9 screening and targeted validation to define DNA damage-response genes that regulate calicheamicin sensitivity in acute leukemia. TP53 loss markedly reduced calicheamicin activity, whereas MDM2 and ATM inhibition enhanced cytotoxicity through partly distinct mechanisms, suggesting biomarker-guided combinations for gemtuzumab ozogamicin and inotuzumab ozogamicin research.

• SAN-Plexus Assembloids Model Pacemaker Maturation

  2026-08-29

  This Cell Stem Cell study develops human pluripotent stem cell-derived assembloids that combine sinoatrial node, cardiac plexus, and atrial-like organoids to model neural regulation of pacemaker activity. Integration with human SAN spatial transcriptomics identifies a prosaposin–GPR37 signaling axis associated with pacemaker maturation and establishes a functional platform for studying conduction disorders.

• From Barrier Biology to Better Biotin Imaging

  2026-08-28

  Biohybrid microrobots may improve access to difficult tumor environments, but translational progress depends on proving where these systems travel and what they engage. This thought-leadership article connects the deformable, magnetically guided Euglena gracilis platform reported in Microsystems & Nanoengineering with Streptavidin-Cy3 as a modular fluorescent readout for biotinylated targets across tissue imaging, nucleic-acid detection, and flow cytometry.

• Phosbind Acrylamide: SDS-PAGE Phosphorylation Guide

  2026-08-28

  Phosbind Acrylamide is a phosphate-binding reagent for resolving phosphorylation-dependent mobility differences during SDS-PAGE without relying on phospho-specific antibodies. It is best used for comparative protein phosphorylation analysis and kinase-related workflows, but it should not be treated as a site-mapping, stoichiometry, or universally validated assay for every protein.

• S Tag Peptide: Practical Fusion-Tag Workflow

  2026-08-27

  S Tag Peptide is a 15-amino-acid RNase A-derived tag used to support protein solubility improvement and antibody-based detection of recombinant fusions. It is appropriate for construct development and protein expression and purification workflows, but ethanol-based handling and long-term storage of aqueous solutions should be avoided.

• ABT-888 (Veliparib): Reliable Viability Assays

  2026-08-27

  A scenario-based guide to using ABT-888 (Veliparib), SKU A3002, in viability, proliferation, and cytotoxicity workflows. It connects PARP1/2 inhibition with practical stock preparation, combination studies, assay controls, and interpretation of sensitization data.

• Vancomycin Hydrochloride in Assay Design

  2026-08-26

  Vancomycin hydrochloride is more than a Gram-positive control: its target biology can guide endpoint selection, resistance interpretation, and infection-model design. This article connects product specifications with a ceftolozane-tazobactam study to develop a practical, mechanism-aware assay framework.

• CPI-613 and the Metabolic Logic of Cuproptosis

  2026-08-26

  CPI-613 offers a research strategy for connecting mitochondrial carbon metabolism with regulated cell death. This thought-leadership article translates recent PDHA1–acetylation findings in resistant prostate cancer into a cautious, testable framework for apoptosis assays, tumor cell metabolism studies, and future combination research.

• Meropenem Workflows for Carbapenem Resistance Research

  2026-08-25

  Build reproducible Meropenem assays for susceptibility testing, resistance surveillance, and Gram-negative infection models. The workflow connects β-lactam pharmacology with plasmid transmission analysis while highlighting practical controls for unstable solutions, inoculum drift, and genotype–phenotype discordance.

• BRD4, TXNIP, and Ferroptosis Sensitivity

  2026-08-25

  The reference study identifies a BRD4–TXNIP–UFMylation pathway that explains how JQ1 increases ferroptosis sensitivity in solid tumor cells. Its central advance is to show that BET inhibition can alter c-MYC chromatin activity and cell-state transitions without relying solely on direct c-MYC repression, providing a mechanistic rationale for combining BET inhibition with ferroptosis-inducing strategies.

• GnRH Antagonists: Position-3 Design and Activity

  2026-08-24

  Samant and colleagues examined how replacing the position-3 residue of degarelix with racemic 3-(2-methoxy-5-pyridyl)-alanine affected GnRH receptor antagonism and duration of action. The D-configured analog retained nanomolar in-vitro potency, whereas the L-configured diastereomer was substantially weaker; both compounds were short-acting in castrated male rats, separating receptor potency from pharmacokinetic persistence.

8076 records 1/539 page Next 12345 下5页 Last page